This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gisby, J.
Right arrow Articles by Bryant, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gisby, J.
Right arrow Articles by Bryant, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2000, p. 255-260, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Efficacy of a New Cream Formulation of Mupirocin: Comparison with Oral and Topical Agents in Experimental Skin Infections

John Gisby* and Joanna Bryantdagger

SmithKline Beecham Pharmaceuticals, Brockham Park, Betchworth, United Kingdom

Received 24 May 1999/Returned for modification 28 July 1999/Accepted 3 November 1999

A new cream formulation of mupirocin developed to improve patient compliance was compared with systemic and topical antibiotics commonly used to treat primary and secondary skin infections. A mouse surgical wound model infected with Staphylococcus aureus or Streptococcus pyogenes was used. Topical treatment was applied at 4 and 10 h postinfection or oral treatment at a clinically relevant dose was administered 4, 8, and 12 h postinfection; treatments were continued three times daily for a further 3 days. Mupirocin cream was significantly more effective than (P < 0.01; two of eight studies) or not significantly different from (six of eight studies) mupirocin ointment in reducing bacterial numbers. Mupirocin cream was similar in efficacy to oral flucloxacillin but significantly more effective (P < 0.001) than oral erythromycin. It was also similar in efficacy to cephalexin against S. pyogenes but superior against S. aureus (P < 0.01). Mupirocin cream had a similar efficacy to fusidic acid cream against S. aureus but was significantly superior against S. pyogenes (P < 0.01). A hamster impetigo model infected with S. aureus was also used. Topical or oral treatment was administered at 24 and 30 h postinfection (also 36 h postinfection for oral therapy) and then three times daily for a further 2 days. On day 5, mupirocin cream was significantly more effective than mupirocin ointment in one study (P < 0.01) and of similar efficacy in the other two studies. Mupirocin cream was not significantly different from fusidic acid cream or neomycin-bacitracin cream, but it was significantly superior (P < 0.01) to oral erythromycin and cephalexin. Mupirocin cream was as effective as, or superior to, oral and other topical agents commonly used for skin infections.

* Corresponding author. Mailing address: c/o Dr. Andrew Smith, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (South), Harlow, Essex CM19 5AW, United Kingdom. Phone: 44-1279-622000. Fax: 44-1279-644100. E-mail: 101324.1256{at}compuserve.com.

dagger Present address: SmithKline Beecham Pharmaceuticals, Collegeville, Philadelphia, Pa.

Antimicrobial Agents and Chemotherapy, February 2000, p. 255-260, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Pettit, R. K., Weber, C. A., Lawrence, S. B., Pettit, G. R., Kean, M. J., Cage, G. D. (2009). In vivo activity of anprocide alone, and in vitro activity in combination with conventional antibiotics against Staphylococcus aureus and Staphylococcus epidermidis biofilms. J Med Microbiol 58: 1203-1206 [Abstract] [Full Text]  
  • Al-Hammadi, H., Hammadi, A. A. (2008). Answer: Can you identify this condition?. cfp 54: 197-197 [Full Text]  
  • Kratzer, C., Tobudic, S., Macfelda, K., Graninger, W., Georgopoulos, A. (2007). In Vivo Activity of a Novel Polymeric Guanidine in Experimental Skin Infection with Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 3437-3439 [Abstract] [Full Text]  
  • Driscoll, D. G., Young, C. L., Ochsner, U. A. (2007). Transient Loss of High-Level Mupirocin Resistance in Staphylococcus aureus Due to MupA Polymorphism. Antimicrob. Agents Chemother. 51: 2247-2248 [Abstract] [Full Text]  
  • Rittenhouse, S., Singley, C., Hoover, J., Page, R., Payne, D. (2006). Use of the Surgical Wound Infection Model To Determine the Efficacious Dosing Regimen of Retapamulin, a Novel Topical Antibiotic. Antimicrob. Agents Chemother. 50: 3886-3888 [Abstract] [Full Text]  
  • Kugelberg, E., Norstrom, T., Petersen, T. K., Duvold, T., Andersson, D. I., Hughes, D. (2005). Establishment of a Superficial Skin Infection Model in Mice by Using Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 49: 3435-3441 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»